Presentation is loading. Please wait.

Presentation is loading. Please wait.

A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. GINA:

Published byRudolf Deák Modified over 6 years ago

Similar presentations

Presentation on theme: "A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. GINA:"— Presentation transcript:

1 A stepwise therapeutic approach in severe uncontrolled asthmatic subjects.
A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. GINA: Global Initiative for Asthma; ICS: inhaled corticosteroid; MDI: metered dose inhaler; DPI: dry powder inhaler; FENO: exhaled nitric oxide fraction; EOS: eosinophils; OCS: oral corticosteroid; IL-5: interleukin-5; IL-4Rα: interleukin-4 receptor α; LTRA: leukotriene receptor antagonist; CRTh2: chemoattractant receptor-homologous molecule expressed on T-helper 2 cells; SPT: skin prick test; NEU: neutrophils; CXCR2: C-X-C motif chemokine receptor 2; LAMA: long-acting muscarinic antagonist; BHR: bronchial hyperresponsiveness; ACO: asthma–chronic obstructive pulmonary disease overlap. Dark blue boxes correspond to currently available treatment options; light blue boxes correspond to future treatments. Eleftherios Zervas et al. ERJ Open Res 2018;4: ©2018 by European Respiratory Society

Download ppt "A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. GINA:"

Similar presentations

Global Initiative for Asthma (GINA) What’s new in GINA 2015?

Global Initiative for Asthma (GINA) What’s new in GINA 2015?
내과 R2 이지영. INTRODUCTION  Asthma  Allergic airway inflammation,Th2-weighted process  Biomarkers  Phenotypic distinctions  Development of personalized.

내과 R2 이지영. INTRODUCTION  Asthma  Allergic airway inflammation,Th2-weighted process  Biomarkers  Phenotypic distinctions  Development of personalized.
Asthma Yardstick Annals of Allergy, Asthma & Immunology

Asthma Yardstick Annals of Allergy, Asthma & Immunology
Global Initiative for Asthma (GINA) What’s new in GINA 2015?

Global Initiative for Asthma (GINA) What’s new in GINA 2015?
Antonio Anzueto, MD, Marc Miravitlles, MD  CHEST 

Antonio Anzueto, MD, Marc Miravitlles, MD  CHEST 
The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD

The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD
Rohit K. Katial, MD, Greg W. Bensch, MD, William W

Rohit K. Katial, MD, Greg W. Bensch, MD, William W
Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to previous chronic obstructive.

Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to previous chronic obstructive.
Endotype-driven care pathways in patients with chronic rhinosinusitis

Endotype-driven care pathways in patients with chronic rhinosinusitis
Asthma diagnosis and treatment: Filling in the information gaps

Asthma diagnosis and treatment: Filling in the information gaps
Severe Asthma in Primary Care: Identification and Management

Severe Asthma in Primary Care: Identification and Management
Discoidin domain receptor (DDR)2 protein was highly expressed in the lungs of patients with interstitial lung disease (ILD). Discoidin domain receptor.

Discoidin domain receptor (DDR)2 protein was highly expressed in the lungs of patients with interstitial lung disease (ILD). Discoidin domain receptor.
Peter J. Barnes, FMedSci, FRS 

Peter J. Barnes, FMedSci, FRS 
Ventilatory and cerebrovascular responses to hyperoxic hypercapnia.

Ventilatory and cerebrovascular responses to hyperoxic hypercapnia.
Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.
Relationship between the change in a) ventilatory and b) cerebrovascular responses in older healthy subjects (Older) and chronic obstructive pulmonary.

Relationship between the change in a) ventilatory and b) cerebrovascular responses in older healthy subjects (Older) and chronic obstructive pulmonary.
Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.

Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.
A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,

A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,
Effects of reslizumab on: (a) clinical asthma exacerbation (CAE) rates; (b) rates of clinical asthma exacerbation requiring oral corticosteroids (OCS);

Effects of reslizumab on: (a) clinical asthma exacerbation (CAE) rates; (b) rates of clinical asthma exacerbation requiring oral corticosteroids (OCS);
Two different pathways lead to eosinophilic airway inflammation in asthma. Two different pathways lead to eosinophilic airway inflammation in asthma. In.

Two different pathways lead to eosinophilic airway inflammation in asthma. Two different pathways lead to eosinophilic airway inflammation in asthma. In.

Similar presentations

Ads by Google